Skip to content
Screener

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Gilead Sciences logo
Gilead SciencesGILD
-$10.35B-389%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$31.65M-867%
CTO
Citius Oncology, Inc.CTOR
-$600K+58.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$40.68M-23.8%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$17.59M-16.7%

Other financials

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Cash & equivalents$110.8M-16.4%
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation

See full
Market cap$2.87B+303%
Enterprise value$2.81B+344%
P/S8.8×+5.9×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp
FCF margin-91.2%-22.1pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 9:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091716
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Maturities of investments135,000210,000
Purchase of investments(185,607)(166,619)
Purchase of property and equipment(12,049)(13,672)
Net cash provided by (used in) investing activities(62,656)29,709
Cash Flows from Financing Activities
Tax payments related to shares withheld for vested restricted stock units(5,345)(6,148)
Proceeds from the issuance of common stock under employee stock purchase plan861669
Proceeds from the issuance of common stock upon exercise of options2615

Item 1.Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Iovance Biotherapeutics, Inc.'s investing cash flow?
Iovance Biotherapeutics, Inc. (IOVA) reported investing cash flow of -$74.05M in Q2 2026.
How has Iovance Biotherapeutics, Inc.'s investing cash flow changed year-over-year?
Iovance Biotherapeutics, Inc.'s investing cash flow decreased by 635.0% year-over-year, from $13.84M to -$74.05M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s investing cash flow has grown at a 611.3% compound annual growth rate (CAGR), from $132K to $47.5M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Iovance Biotherapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude